Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial

Conclusion Among high-risk patients with atrial fibrillation who experienced major bleeding in ROCKET AF, the use of FFP and PCC was less among those allocated rivaroxaban compared with warfarin. However, use of PRBCs and outcomes after bleeding were similar among patients randomized to rivaroxaban or to warfarin.
Source: European Heart Journal - Category: Cardiology Authors: Tags: Atrial fibrillation Source Type: research